Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer Test and MyRisk Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink. This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered directly within BxLink’s intuitive platform. By replacing manual processes, the integration will reduce errors and aims to deliver molecular testing results to clinicians in an average of under 10 days after specimen collection.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Biote announcesTerry Weber retires Bret Christensen named CEO
- Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
- Myriad Genetics unveils resesrch at SMFM on cfDNA
- Myriad Genetics introduces online prenatal genetic testing resource
- Myriad Genetics announces hereditary cancer risk assessment study published